News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Pfizer and Moderna are also working on vaccines that target the Omicron variant
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
